Treatment Response to Sofosbuvir and Ribavirin in Chronic Hepatitis C Patients and Comparison of Naive and Treatment Experienced Patients
Background: Sofosbuvir is on the world organization’s list of essential medicines, the most effective and safe medicines needed in health system. It plays a special role in treatment of chronic hepatitis C and offers many advantages due to its high potency, low side effects, oral administration, and...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Rawalpindi Medical University
2018-12-01
|
| Series: | Journal of Rawalpindi Medical College |
| Subjects: | |
| Online Access: | https://www.journalrmc.com/index.php/JRMC/article/view/991 |
| Summary: | Background: Sofosbuvir is on the world organization’s list of essential medicines, the most effective and safe medicines needed in health system. It plays a special role in treatment of chronic hepatitis C and offers many advantages due to its high potency, low side effects, oral administration, and high barrier to resistance.
Objectives: To compare the treatment response in treatment naive and treatment experienced chronic hepatitis C patients treated with sofosbuvir and ribavirin to determine the efficacy of this drug combination.
Methods: In this experimental study 104 chronic hepatitis C patients with positive polymerase chain reaction (PCR) for hepatitis C virus (HCV) and high alanine aminotransferase (ALT) levels were included. Out of them 66 (63.5%) were treatment naive (received treatment for the first time) and 38 (36.5%) were treatment experienced. Sofosbuvir 400mg once a day in combination with ribavirin was given for 6 months and treatment responses were noted at 4, 12 and 24 weeks. SPSS version 21 was used to analyze the data.
Results: The end treatment response in 104 chronic hepatitis C patients was calculated in which 99 (95.2%) patients responded to the therapy. 63 (95.5%) treatment naive patients and 36 (94.7%) treatment experienced responded to the therapy. End treatment response (ETR) in chronic hepatitis C patients to sofosbuvir and ribavirin was irrespective to their gender and genotypes and test of significance came out as insignificant (p > 0.05).
Conclusion: Sofosbuvir is effective for both treatment naive and treatment experienced chronic hepatitis C patients. This regimen is equally effective for both genders and all genotypes of hepatitis C.
Keywords: , , , , , . |
|---|---|
| ISSN: | 1683-3562 1683-3570 |